News
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
DGAP-News: Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India
DGAP-News: Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India
DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
DGAP-News: Evotec SE reports results for the first quarter 2022 and provides corporate update
DGAP-News: Evotec SE reports results for the first quarter 2022 and provides corporate update
DGAP-News: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
DGAP-News: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
Gerresheimer AG: Gerresheimer and Portal enter strategic partnership to treat chronically ill patients with innovative needle-free drug-delivery solution
Gerresheimer AG: Gerresheimer and Portal enter strategic partnership to treat chronically ill patients with innovative needle-free drug-delivery solution
DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results
DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results
DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results
DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results
DGAP-News: Evotec SE to announce results for the first quarter 2022 on 11 May 2022
DGAP-News: Evotec SE to announce results for the first quarter 2022 on 11 May 2022
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
MorphoSys: Dieser Rücksetzer ist kaufenswert!
Die in Martinsried bei München beheimatete MorphoSys (WKN: 663200) ist aus meiner Sicht, zusammen mit der Hamburger Evotec, das beste deutsche Biotechnologieunternehmen.
Dies konnte man auch erst
MorphoSys: Dieser Rücksetzer ist kaufenswert!
Die in Martinsried bei München beheimatete MorphoSys (WKN: 663200) ist aus meiner Sicht, zusammen mit der Hamburger Evotec, das beste deutsche Biotechnologieunternehmen.
Dies konnte man auch erst
Sartorius: Unternehmen profitiert von der Corona-Krise
Ein absoluter Highflyer am deutschen Aktienmarkt ist schon seit vielen Jahren die Vorzugsaktie des Göttinger Laborausrüsters Sartorius (WKN: 716563). Dies ist umso erstaunlicher, da noch zu Neuer
Sartorius: Unternehmen profitiert von der Corona-Krise
Ein absoluter Highflyer am deutschen Aktienmarkt ist schon seit vielen Jahren die Vorzugsaktie des Göttinger Laborausrüsters Sartorius (WKN: 716563). Dies ist umso erstaunlicher, da noch zu Neuer
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
Toronto Innovation Acceleration Partners (“TIAP”) and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the two companies have expanded
DGAP-News: Evotec SE veröffentlicht Ergebnisse des Geschäftsjahres 2021: 'Setting the Pace' auf der 'data-driven R&D Autobahn to Cures'
DGAP-News: Evotec SE veröffentlicht Ergebnisse des Geschäftsjahres 2021: 'Setting the Pace' auf der 'data-driven R&D Autobahn to Cures'
DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures
DGAP-News: Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures